<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467726</url>
  </required_header>
  <id_info>
    <org_study_id>0048</org_study_id>
    <nct_id>NCT01467726</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Placebo−Controlled, Double−Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma R &amp; D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, Randomized, Placebo−Controlled, Double−Blind, Study of Safety,
      Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of repeat dosing of velusetrag</measure>
    <time_frame>3 weeks</time_frame>
    <description>Number of subjects who complete the treatment period and are not withdrawn due to adverse events (AEs) or clinically significant findings on vital signs or ECGs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of Plasma Pharmacokinetics (PK) of velusetrag and metabolite</measure>
    <time_frame>Days 1, 7, 8, 14, 15, 21 at predose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours postdose and 24 hours postdose (and 48 and 72 h post Day 21 dose)</time_frame>
    <description>Cmax (maximum observed concentration), Tmax (time of maximum observed concentration), AUC (area under the concentration-time curve)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of urine PK of velusetrag and metabolite</measure>
    <time_frame>Days 1, 7, 8, 14, 15, 21 0-24h postdose and 24-72 h post Day 21 dose</time_frame>
    <description>Ae (amount excreted in urine), fe (fraction excreted in urine), CLr (renal clearance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects of velusetrag</measure>
    <time_frame>3 weeks</time_frame>
    <description>weekly bowel movement frequency</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Dose regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varied doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varied doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velusetrag</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Dose regimen 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velusetrag</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Dose regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Is in reasonably good health as determined by the investigator based on a detailed
        medical history, full physical examination (PE), vital signs (VS) (including blood pressure
        and pulse rate measurement), 12-lead ECG, and clinical laboratory tests.

          -  Subjects with mild, chronic, stable disease (e.g., controlled hypertension, controlled
             hypercholesterolemia, non-insulin dependent diabetes, osteoarthritis) may be enrolled
             if well controlled and not anticipated to interfere with the objectives of the study.

          -  Mild deviations from normal limits in PE, VS, ECG parameters, lab tests are acceptable
             if associated with the stable condition or are age-related

        Exclusion Criteria:

          -  Has a condition, which in the opinion of the investigator, would confound or interfere
             with evaluation of safety and tolerability or PK or PD of the investigational drug, or
             prevent compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Comprehensive Clinical Development</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>December 1, 2014</last_update_submitted>
  <last_update_submitted_qc>December 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

